The Genetics of Pulmonary Arterial Hypertension #MMPMID24951767
Austin ED; Loyd JE
Circ Res 2014[Jun]; 115 (1): 189-202 PMID24951767show ga
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease for which there is an ever-expanding body of genetic and related pathophysiological information on disease pathogenesis. A number of germline gene mutations have now been described, including mutations in the gene coding bone morphogenic protein receptor type 2 (BMPR2) and related genes. Recent advanced gene sequencing methods have facilitated the discovery of additional genes with mutations among those with and without familial forms of PAH (CAV1, KCNK3, EIF2AK4). The reduced penetrance, variable expressivity, and female predominance of PAH suggest that genetic, genomic and other factors modify disease expression. These multi-faceted variations are an active area of investigation in the field, including but not limited to common genetic variants and epigenetic processes, and may provide novel opportunities for pharmacologic intervention in the near future. They also highlight the need for a systems-oriented multi-level approach to incorporate the multitude of biologic variations now associated with PAH. Ultimately, improved understanding provides the opportunity for improved patient and family counseling about this devastating disease, but do require in depth understanding of the genetic factors relevant to PAH.
free
free
free
Circ+Res 2014 ; 115 (1): 189-202
